Trial Profile
A combination study to evaluate ZL-2301 with anti-PD1 therapy for hepatocellular carcinoma (HCC) patients in China
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2018
Price :
$35
*
At a glance
- Drugs Brivanib alaninate (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 05 Oct 2018 New trial record